Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors

Han,Fuxin; Zhang,Jinsong; Ma,Shanbo; Chen,Xiaoyan; Liu,Weiping; He,Xiaosheng; Fei,Zhou; Wang,Yangang

doi:10.3892/ol.2017.7460

Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors

Authors:
- Fuxin Han
- Jinsong Zhang
- Shanbo Ma
- Xiaoyan Chen
- Weiping Liu
- Xiaosheng He
- Zhou Fei
- Yangang Wang
View Affiliations

Affiliations: Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: November 21, 2017 https://doi.org/10.3892/ol.2017.7460
Pages: 1459-1468
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To evaluate the prognostic significance of the altered expression of capicua transcriptional repressor (CIC) in isocitrate dehydrogenase (IDH)‑mutant oligodendroglial tumors, a cohort of 54 IDH‑mutant oligodendroglial tumors (designated as the Xijing cohort) were examined by immunohistochemistry (IHC), and two public expression data sets from The Cancer Genome Atlas (TCGA; n=265) and the Gene Expression Omnibus (GEO; n=45) were analyzed in the present study. The prognostic value was evaluated by survival analysis and Cox hazards models. Overall survival (OS) was investigated with Kaplan‑Meier curves and log‑rank tests. Gene set enrichment analysis (GSEA) was also performed to characterize the functional profiles of each subgroup. It was revealed that in IDH‑mutant, 1p/19q co‑deleted oligodendroglial tumors, higher CIC expression (at mRNA and protein levels) was associated with a more favorable OS time (log‑rank P‑values: TCGA, P=0.034; GEO, P=0.012; Xijing cohort, P=0.029). By contrast, among IDH‑mutant, 1p/19q intact tumors, higher CIC expression was associated with poorer OS time (log‑rank P‑values: TCGA, P=0.007; GEO, P=0.017; Xijing cohort, P=0.012). To the best of our knowledge, this is the first study demonstrating the distinct prognostic value of altered CIC expression with regard to the 1p/19q status among IDH‑mutant oligodendroglial tumors. The dual roles of CIC may be influenced by its transcriptional regulatory activity and the consequent functional profiles. Additionally, a simple risk classification scheme based on CIC expression alone is proposed for the optimal prediction of prognosis in patients with oligodendroglial tumors.

View Figures

View References

1	Cancer Genome Atlas Research Network, ; Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, et al: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 372:2481–2498. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wesseling P, van den Bent M and Perry A: Oligodendroglioma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 129:809–827. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A and Hartmann C: CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. 123:853–860. 2012. View Article : Google Scholar : PubMed/NCBI
4	Gleize V, Alentorn A, Connen de Kérillis L, Labussière M, Nadaradjane AA, Mundwiller E, Ottolenghi C, Mangesius S, Rahimian A, Ducray F, et al: CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol. 78:355–374. 2015. View Article : Google Scholar : PubMed/NCBI
5	Van Den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, et al: Adjuvant procarbazine, lomustine and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 31:344–350. 2013. View Article : Google Scholar : PubMed/NCBI
6	Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, et al: ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an ‘integrated’ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 129:133–146. 2015. View Article : Google Scholar : PubMed/NCBI
7	Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, et al: Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3:709–722. 2012. View Article : Google Scholar : PubMed/NCBI
8	Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, et al: Concurrent CIC mutations, IDH mutations and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 226:7–16. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chan AK, Pang JC, Chung NY, Li KK, Poon WS, Chan DT, Shi Z, Chen L, Zhou L and Ng HK: Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol. 27:332–342. 2014.PubMed/NCBI
10	Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, et al: Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 333:1453–1455. 2011. View Article : Google Scholar : PubMed/NCBI
11	Jimenez G, Shvartsman SY and Paroush Z: The Capicua repressor-a general sensor of RTK signaling in development and disease. J Cell Sci. 125:1383–1391. 2012. View Article : Google Scholar : PubMed/NCBI
12	Fuller GN and Scheithauer BW: The 2007 revised World Health Organization (WHO) classification of tumours of the central nervous system: Newly codified entities. Brain Pathol. 17:304–307. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chen X, Yun J, Fei F, Yi J, Tian R, Li S and Gan X: Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol Res Pract. 208:437–443. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 69:9065–9072. 2009. View Article : Google Scholar : PubMed/NCBI
15	Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG, den Dunnen WF, Teepen JL, Wesseling P, Sillevis Smitt PA, et al: Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951. J Clin Oncol. 31:328–336. 2013. View Article : Google Scholar : PubMed/NCBI
16	Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, et al: Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 14:2056–2064. 2008. View Article : Google Scholar : PubMed/NCBI
17	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:pp. 15545–15550. 2005; View Article : Google Scholar : PubMed/NCBI
18	Hothorn T and Zeileis A: Generalized maximally selected statistics. Biometrics. 64:1263–1269. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chittaranjan S, Chan S, Yang C, Yang KC, Chen V, Moradian A, Firme M, Song J, Go NE, Blough MD, et al: Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lee CJ, Chan WI and Scotting PJ: CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J Neurooncol. 73:101–108. 2005. View Article : Google Scholar : PubMed/NCBI